Pancreatic cancer patients with low tumor expression of nucleoside transporters show significantly worse survival compared to patients with high hENT1 and hCNT3 levels following gemcitabine treatment [69,70,71,72]. This evidence concerns the gene SLC29A1 and familial pancreatic carcinoma.